AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by AC Immune SA, a foreign private issuer, on March 22, 2022. The filing covers the month of March 2022 and serves to distribute the company's 2021 annual reports and financial statements to the U.S. Securities and Exchange Commission.
Key Financial Metrics
The filing text provided is a cover sheet and exhibit index. It does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits, specifically the "2021 IFRS Consolidated Financial Statements" (Exhibit 99.2) and the "2021 Statutory Annual Report" (Exhibit 99.3).
Material Changes
The provided text does not detail material changes versus the prior comparable period. Such analysis is expected to be found in the full 2021 financial statements and annual report referenced in the exhibit index.
Guidance, Outlook, and Risks
The filing includes a press release dated March 22, 2022 (Exhibit 99.1), which likely contains management commentary, outlook, and risk factors. However, the specific content of this press release is not included in the provided text. The filing also references a 2021 Compensation Report (Exhibit 99.4).
Investor Verification Checklist
- Review Exhibit 99.2 (2021 IFRS Consolidated Financial Statements) for actual revenue, net loss, and cash position figures.
- Examine Exhibit 99.1 (Press Release) for updates on clinical trial progress, partnership developments, and forward-looking guidance.
- Consult Exhibit 99.3 (2021 Statutory Annual Report) for a comprehensive overview of operational risks and strategic direction.
- Verify the company's cash runway and burn rate based on the 2021 financial data to assess liquidity needs for 2022.